Covance
announced the expansion of its drug metabolism services to include drug-transporter interactions with eight human transporters. Under this expansion, Covance now offers assessment of drug-transporter interactions involving major human transporters key to drug disposition in a stably transfected, cell-based format regarded as a superior model for reliable, reproducible results.
“For more than 30 years, Covance has helped our clients achieve a detailed understanding of the disposition of their drug candidates,” said Jon Denissen, PhD, Vice President of Global Drug Metabolism. “The addition of drug-transporter interactions to our service offering enables our clients to define the importance of transporters in their drug discovery and development programs, select the best drug candidates, and meet the latest expectations of regulatory agencies.”
Eight cell lines stably expressing human transporters in the Covance drug-transporter interactions service include P-glycoprotein (P-gp/MDR1), breast cancer resistant protein (BCRP), organic cation transporters 1& 2 (OCT1 & OCT2), organic anion transporter 3 (OAT3), organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1 & OATP1B3), and multidrug resistance-associated protein 2 (MRP2).
Through its wholly-owned laboratories located in the United States, Europe, and Asia, Covance offers clients access to comprehensive and integrated portfolios of drug metabolism services, including preclinical PK,
in vitro
metabolism, custom radiosynthesis,
in vivo
radiolabeled ADME, metabolite identification, and PK/TK analysis.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.